pharmaceutical solutions

Summary

Summary: Homogeneous liquid preparations that contain one or more chemical substances dissolved, i.e., molecularly dispersed, in a suitable solvent or mixture of mutually miscible solvents. For reasons of their ingredients, method of preparation, or use, they do not fall into another group of products.

Top Publications

  1. ncbi Pharmaceutical development of a parenteral lyophilised dosage form for the novel anticancer agent C1311
    Monique W J den Brok
    Slotervaart Hospital The Netherlands Cancer Institute, Department of Pharmacy and Pharmacology, Amsterdam
    PDA J Pharm Sci Technol 59:285-97. 2005
  2. doi Stability of norepinephrine infusions prepared in dextrose and normal saline solutions
    Maryse Tremblay
    Department of Anesthesiology, Centre Hospitalier Affilie Universitaire De Quebec, Universite Laval, Quebec City, Quebec, Canada
    Can J Anaesth 55:163-7. 2008
  3. ncbi Characterization of a potential medium for 'biorelevant' in vitro release testing of a naltrexone implant, employing a validated stability-indicating HPLC method
    Sunil S Iyer
    Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298 0533, USA
    J Pharm Biomed Anal 43:845-53. 2007
  4. ncbi Stability of oral liquid preparations of methylergometrine
    K Marigny
    Laboratory of Analytical Chemistry, Faculty of Pharmacy, University of Rennes, France
    Pharmazie 61:701-5. 2006
  5. ncbi Study of insolubility problems of dexamethasone and digoxin: cyclodextrin complexation
    V Dilova
    Department of Galenical, Chemical Pharmaceutical Research Institute, Sofia, Bulgaria
    Boll Chim Farm 143:20-3. 2004
  6. ncbi Ranitidine (Zantac) syrup versus Ranitidine effervescent tablets (Zantac) EFFERdose) in children: a single-center taste preference study
    Vanessa Z Ameen
    Clinical Pharmacology and Discovery Medicine, Research and Development, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    Paediatr Drugs 8:265-70. 2006
  7. doi Acceptance of uncoated mini-tablets in young children: results from a prospective exploratory cross-over study
    Natalie Spomer
    Department of General Paediatrics and Neonatology, University Children s Hospital, Dusseldorf, Germany
    Arch Dis Child 97:283-6. 2012
  8. ncbi Particulate and microbial contamination in in-use admixed intravenous infusions
    Katsuhiro Yorioka
    Department of Pharmacy, Saiseikai Yamaguchi University Hospital, Japan
    Biol Pharm Bull 29:2321-3. 2006
  9. ncbi Three simultaneous dissolution profiles on a solid pharmaceutical formulation by a FIA manifold provided with a single spectrophotometric detector
    E Vranic
    Department of Analytical Chemistry, University of Valencia, Moliner 50, 46100 Burjassot, Valencia, Spain
    J Pharm Biomed Anal 33:1039-48. 2003
  10. ncbi Extemporaneous procedures for dissolving risedronate tablets for oral administration and for feeding tubes
    Richard J Dansereau
    Procter and Gamble Pharmaceuticals, Mason, OH 45040 9462, USA
    Ann Pharmacother 39:63-7. 2005

Detail Information

Publications182 found, 100 shown here

  1. ncbi Pharmaceutical development of a parenteral lyophilised dosage form for the novel anticancer agent C1311
    Monique W J den Brok
    Slotervaart Hospital The Netherlands Cancer Institute, Department of Pharmacy and Pharmacology, Amsterdam
    PDA J Pharm Sci Technol 59:285-97. 2005
    ..The drug is currently used in phase I clinical trials...
  2. doi Stability of norepinephrine infusions prepared in dextrose and normal saline solutions
    Maryse Tremblay
    Department of Anesthesiology, Centre Hospitalier Affilie Universitaire De Quebec, Universite Laval, Quebec City, Quebec, Canada
    Can J Anaesth 55:163-7. 2008
    ..Data on long term stability of NE solutions are lacking. This prospective study was designed to evaluate the stability of NE, in dextrose (5%) in water (D5W) and in normal saline (NS) solutions, for a period up to seven days...
  3. ncbi Characterization of a potential medium for 'biorelevant' in vitro release testing of a naltrexone implant, employing a validated stability-indicating HPLC method
    Sunil S Iyer
    Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298 0533, USA
    J Pharm Biomed Anal 43:845-53. 2007
    ..This was applied to an investigation of in vitro drug release. The method has been proven to be suitable for investigation of naltrexone released from the implant...
  4. ncbi Stability of oral liquid preparations of methylergometrine
    K Marigny
    Laboratory of Analytical Chemistry, Faculty of Pharmacy, University of Rennes, France
    Pharmazie 61:701-5. 2006
    ..No degradation products were revealed. This study allowed an oral ready to use solution of methylergometrine (0.05 mg/ml) to be prepared, with a shelf life of more than one month (47 days) when stored at room temperature without light...
  5. ncbi Study of insolubility problems of dexamethasone and digoxin: cyclodextrin complexation
    V Dilova
    Department of Galenical, Chemical Pharmaceutical Research Institute, Sofia, Bulgaria
    Boll Chim Farm 143:20-3. 2004
    ..The same results can be achieved through HP beta CD, by including Dex in a multicomponent composition containing HP beta CD and citric acid in a molar ratio of 1:4:1...
  6. ncbi Ranitidine (Zantac) syrup versus Ranitidine effervescent tablets (Zantac) EFFERdose) in children: a single-center taste preference study
    Vanessa Z Ameen
    Clinical Pharmacology and Discovery Medicine, Research and Development, GlaxoSmithKline, Research Triangle Park, North Carolina 27709, USA
    Paediatr Drugs 8:265-70. 2006
    ..Ranitidine syrup is available in a peppermint-flavored 15 mg/mL formulation...
  7. doi Acceptance of uncoated mini-tablets in young children: results from a prospective exploratory cross-over study
    Natalie Spomer
    Department of General Paediatrics and Neonatology, University Children s Hospital, Dusseldorf, Germany
    Arch Dis Child 97:283-6. 2012
    ..To explore the acceptance of uncoated drug-free mini-tablets 2 mm in diameter in children aged 0.5-6 years and their ability to swallow the mini-tablets...
  8. ncbi Particulate and microbial contamination in in-use admixed intravenous infusions
    Katsuhiro Yorioka
    Department of Pharmacy, Saiseikai Yamaguchi University Hospital, Japan
    Biol Pharm Bull 29:2321-3. 2006
    ..No microbial contamination was observed in any of the residual solutions of 5 types of admixture...
  9. ncbi Three simultaneous dissolution profiles on a solid pharmaceutical formulation by a FIA manifold provided with a single spectrophotometric detector
    E Vranic
    Department of Analytical Chemistry, University of Valencia, Moliner 50, 46100 Burjassot, Valencia, Spain
    J Pharm Biomed Anal 33:1039-48. 2003
    ..The analytical errors when the concentration of one drug is very small or very high are also checked...
  10. ncbi Extemporaneous procedures for dissolving risedronate tablets for oral administration and for feeding tubes
    Richard J Dansereau
    Procter and Gamble Pharmaceuticals, Mason, OH 45040 9462, USA
    Ann Pharmacother 39:63-7. 2005
    ..Extemporaneous procedures for dissolving tablets for feeding tubes and for preparation of an oral liquid have not previously been evaluated...
  11. ncbi In vivo performance of an oral MR matrix tablet formulation in the beagle dog in the fed and fasted state: assessment of mechanical weakness
    Fiona McInnes
    Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK
    Pharm Res 25:1075-84. 2008
    ..To evaluate the behaviour of an oral matrix modified release formulation in the canine gastrointestinal tract, and establish if a mechanical weakness previously observed in clinical studies would have been identified in the dog model...
  12. ncbi Tuning the polymer release from hydrophilic matrix tablets by mixing short and long matrix polymers
    Anna Korner
    Department of Physical Chemistry 1, Center for Chemistry and Chemical Engineering, Lund University, Box 124, SE 221 00, Lund, Sweden
    J Pharm Sci 94:759-69. 2005
    ..The presence of small amounts of additives in the nonpurified commercial samples had no significant effect on the tablet dissolution within the uncertainty of the experiment...
  13. ncbi Development and validation of RP-HPLC method for the analysis of metformin
    M Saeed Arayne
    Department of Chemistry, University of Karachi, Karachi 75270, Pakistan
    Pak J Pharm Sci 19:231-5. 2006
    ..The proposed method is rapid, accurate, economical and selective and it may be used for the quantitative analysis of metformin in Neodipar tablets because of its sensitivity and reproducibility...
  14. ncbi A stability indicating LC method for zolmitriptan
    B Mallikarjuna Rao
    Analytical Research, Custom Pharmaceutical Services, Dr Reddy s Laboratories, Hyderabad 500049, India
    J Pharm Biomed Anal 39:503-9. 2005
    ..The stress samples were assayed against a qualified reference standard and the mass balance was found close to 99.5%. The developed RP-LC method was validated with respect to linearity, accuracy, precision and robustness...
  15. ncbi Is the use of a 200 ml vessel suitable for dissolution of low dose drug products?
    Debbie J Crail
    Procter and Gamble Pharmaceuticals, 8700 Mason Montgomery Road, Mason, OH 45040, USA
    Int J Pharm 269:203-9. 2004
    ..The results of the multiple dosage units per vessel also gave similar results to that of the USP monograph method...
  16. ncbi Influence of histidine on the stability and physical properties of a fully human antibody in aqueous and solid forms
    Bei Chen
    Department of Process Sciences, Abgenix, Inc, Fremont, CA 94555, USA
    Pharm Res 20:1952-60. 2003
    ..The aim of the study was to investigate the effect of histidine on the stability and physical properties of a fully human anti-IL8 monoclonal antibody (ABX-IL8) in aqueous and solid forms...
  17. ncbi Parallel screening approach to identify solubility-enhancing formulations for improved bioavailability of a poorly water-soluble compound using milligram quantities of material
    Wei Guo Dai
    ALZA Corporation, 1900 Charleston Road, Mountain View, CA 94039, USA
    Int J Pharm 336:1-11. 2007
    ....
  18. ncbi Stabilization of rasburicase and physico-chemical characterization of the resulting injectable formulation
    Alain Bayol
    Analytical Science Department, Sanofi Synthelabo Recherche, Labege, France
    Drug Dev Ind Pharm 30:877-89. 2004
    ..Crystallised excipients participate in forming the structure of the powder and therefore help to prevent any collapse. Amorphous mannitol creates a surrounding medium favourable to the stability of the protein...
  19. ncbi Densitometric determination of diclofenac, 1-(2,6-dichlorophenyl)indolin-2-one and indolin-2-one in pharmaceutical preparations and model solutions
    Jan Krzek
    Department of Inorganic and Analytical Chemistry, Collegium Medicum, Jagiellonian University, 9 Medyczna Str, 30 688 Cracow, Poland
    J Pharm Biomed Anal 28:227-43. 2002
    ..34% and for indolin-2-one--95.85%. The method was used for quality assessment of diclofenac in pharmaceutical preparations. Reliable results comparable to those determined by high performance liquid chromatography (HPLC) were obtained...
  20. ncbi Solution-mediated phase transformation of anhydrous to dihydrate carbamazepine and the effect of lattice disorder
    D Murphy
    Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, 428 Church Street, Ann Arbor 48109 1065, USA
    Int J Pharm 246:121-34. 2002
    ..These results have significant consequences on the concentration-time profiles of active pharmaceutical ingredients during dissolution of metastable solid phases, crystalline or amorphous...
  21. ncbi Formulation and evaluation of ketorolac transdermal systems
    Jun Shik Choi
    College of Pharmacy, Chosun University, Gwangju, Korea
    Drug Deliv 14:69-74. 2007
    ..There was an excellent relationship found between in vitro permeation flux and in vivo AUC0-infinity...
  22. doi Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration
    Thomas C Kupie
    Analytical Research Laboratories, Oklahoma City, OK, USA
    Am J Health Syst Pharm 65:1735-59. 2008
    ..The physical and chemical compatibility of palonosetron hydrochloride with atropine sulfate, famotidine, heparin sodium, lidocaine hydrochloride, and potassium chloride during simulated Y-site administration were studied...
  23. ncbi Stability and transdermal absorption of topical amphotericin B liposome formulations
    A Manosroi
    Pharmaceutical Cosmetics Raw Materials and Natural Products Research and Development Center, Faculty of Pharmacy, Institute for Science and Technology Research and Development, Chiang Mai University, Chiang Mai 50200, Thailand
    Int J Pharm 270:279-86. 2004
    ..AmB entrapped in charged liposomes showed sustained skin absorption. The positively charged liposome might be the best formulation for AmB, due to its higher stability than other formulations...
  24. ncbi A validated stability indicating ion-pair RP-LC method for zoledronic acid
    B Mallikarjuna Rao
    Analytical Research, Custom Pharmaceutical Services, Dr Reddy s Laboratories, Hyderabad 500049, India
    J Pharm Biomed Anal 39:781-90. 2005
    ..It can be also used to test the stability samples of zoledronic acid...
  25. ncbi Development of parenteral formulation for a novel angiogenesis inhibitor, CKD-732 through complexation with hydroxypropyl-beta-cyclodextrin
    Jae Hyun Kim
    Pharmaceutical Research Labs, CKD Research Institute, Chong Kun Dang Pharm, P O Box 74, Chonan 330 600, South Korea
    Int J Pharm 272:79-89. 2004
    ..hemioxalate solution with the favorable reduction of irritation. These results demonstrate that the CKD-732/HP-beta-CyD complex is an attractive formulation for use in the parenteral delivery of CKD-732...
  26. ncbi Physical and chemical stability of pemetrexed solutions in plastic syringes
    Yanping Zhang
    Pharmacy Laboratory, The University of Texas, MD Anderson Cancer Center, Houston, 77030, USA
    Ann Pharmacother 39:2026-8. 2005
    ..Currently, there is no information on the long-term stability of pemetrexed solutions beyond 24 hours...
  27. ncbi Enhanced drug dissolution using evaporative precipitation into aqueous solution
    Marazban Sarkari
    Department of Chemical Engineering, University of Texas at Austin, Austin, TX 78712 1062, USA
    Int J Pharm 243:17-31. 2002
    ..The high dissolution rates are a consequence of the following advantages of the EPAS process: a small primary particle size, a hydrophilic coating on the particles that enhances wetting, and low crystallinity...
  28. ncbi Chemical analysis of freshly prepared and stored capsaicin solutions: implications for tussigenic challenges
    Scott E Kopec
    The Division of Pulmonary, Allergy, and Critical Care Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA
    Pulm Pharmacol Ther 15:529-34. 2002
    ..033). We conclude that the actual concentration of capsaicin solution is less than predicted, and solutions of 4 microM or higher concentration are stable for 1 year if stored at 4 degrees C protected from light...
  29. ncbi Physical and chemical stability of pemetrexed in infusion solutions
    Yanping Zhang
    MD Anderson Cancer Center, The University of Texas, Houston, 77030, USA
    Ann Pharmacother 40:1082-5. 2006
    ..Currently, there is no information on the long-term stability of pemetrexed beyond 24 hours...
  30. pmc Variations in captopril formulations used to treat children with heart failure: a survey in the United kingdom
    Hussain Mulla
    Centre for Pharmacy Practice Research, Glenfield Hospital, Leicester, UK
    Arch Dis Child 92:409-11. 2007
    ..The objective of this study was to ascertain the interhospital constancy of unlicensed liquid captopril formulations used to treat children with heart failure in the UK...
  31. ncbi Determination of cetirizine dihydrochloride, related impurities and preservatives in oral solution and tablet dosage forms using HPLC
    A M Y Jaber
    Chemistry Department, King Fahid University of Petroleum and Minerals, Dhahran 31261, Saudi Arabia
    J Pharm Biomed Anal 36:341-50. 2004
    ..28-0.86 microg ml(-1), respectively. The method proved to be specific, stability indicating, accurate, precise, robust and could be used as an alternative to the European pharmacopoeial method set for CZ and its related impurities...
  32. doi In vitro and in vivo considerations associated with parenteral sustained release products: a review based upon information presented and points expressed at the 2007 Controlled Release Society Annual Meeting
    Marilyn Martinez
    US Food and Drug Administration, Center for Veterinary Medicine, Office of New Animal Drug Evaluation, Rockville, Maryland 20855, USA
    J Control Release 129:79-87. 2008
  33. ncbi Oral sustained delivery of paracetamol from in situ gelling xyloglucan formulations
    Shozo Miyazaki
    Faculty of Pharmaceutical Sciences, Health Science University of Hokkaido, Ishikari Tohbetsu, Hokkaido, Japan
    Drug Dev Ind Pharm 29:113-9. 2003
    ....
  34. ncbi Compatibility of palonosetron with cyclophosphamide and with ifosfamide during simulated Y-site administration
    Quanyun A Xu
    Division of Pharmacy, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Am J Health Syst Pharm 62:1998-2000. 2005
    ..The physical and chemical compatibility of palonosetron with cyclophosphamide and with ifosfamide during simulated Y-site administration was studied...
  35. ncbi Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during simulated Y-site administration
    Lawrence A Trissel
    TriPharma Research, Cashiers, NC 28717 0265, USA
    Am J Health Syst Pharm 64:1209-13. 2007
    ..The physical and chemical compatibility of palonosetron hydrochloride with fentanyl citrate, hydromorphone hydrochloride, meperidine hydrochloride, morphine sulfate, and sufentanil citrate during simulated Y-site administration was studied...
  36. ncbi Improving the dissolution rate of poorly water soluble drug by solid dispersion and solid solution: pros and cons
    Rina J Chokshi
    Applied Pharmaceutical Sciences, University of Rhode Island, Kingston, RI 02881, USA
    Drug Deliv 14:33-45. 2007
    ..Therefore, considering physical stability and in vivo study results, the solid dispersion was the most suitable choice to improve dissolution rates and hence the bioavailability of the poorly water soluble drug...
  37. ncbi A stability-indicating HPLC method for medroxyprogesterone acetate in bulk drug and injection formulation
    Jankana Burana-Osot
    Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Silpakorn University, Sanamchandra Palace Campus, Nakhon Pathom 73000, Thailand
    J Pharm Biomed Anal 40:1068-72. 2006
    ..The method was found to be suitable for the quality control of MPA in bulk drug and injections as well as the stability-indicating studies...
  38. ncbi Preparation and characterization of enrofloxacin/carbopol complex in aqueous solution
    Myung Kwan Chun
    College of Pharmacy, Chosun University, Gwangju 501 759, Korea
    Arch Pharm Res 27:670-5. 2004
    ..Therefore, these observations suggest that Carbo-enrofloxacin complex I can be used to mask the taste of enrofloxacin...
  39. ncbi Long-term stabilization of recombinant human interferon alpha 2b in aqueous solution without serum albumin
    Llamil Ruiz
    Formulation Development Department, Center for Genetic Engineering and Biotechnology CIGB, P O Box 6162, Havana, Cuba
    Int J Pharm 264:57-72. 2003
    ..Furthermore, both the physical stability (color, odor, appearance, pH, and absence of particulate material) and the sterility of this formulation were maintained under the proposed shelf conditions...
  40. ncbi Effects of annealing lyophilized and spray-lyophilized formulations of recombinant human interferon-gamma
    Serena D Webb
    Department of Chemical Engineering, University of Colorado, Boulder, Colorado 80309 0424, USA
    J Pharm Sci 92:715-29. 2003
    ....
  41. ncbi A new formulation concept for drugs with poor water solubility for parenteral application
    K Jurgens
    Department for Pharmaceutics and Biopharmaceutics, Christian Albrecht University Kiel, Germany
    Pharmazie 60:665-70. 2005
    ..First in vivo data show good tolerability and blood plasma levels which are comparable to conventional solutions...
  42. ncbi Dissolution test for liquid formulations of omeprazole enteric-coated products
    Hye J Jang
    Ann Pharmacother 37:150-1. 2003
  43. ncbi A mechanistic study of danazol dissolution in ionic surfactant solutions
    Wei Sun
    Department of Chemical and Petroleum Engineering, University of Kansas, Lawrence, Kansas 66045, USA
    J Pharm Sci 92:424-35. 2003
    ..In that situation, the nuclear magnetic resonance (NMR)-measured drug diffusivity would not be its actual value in the dissolution process...
  44. ncbi An explanation for the physical instability of a marketed fixed dose combination (FDC) formulation containing isoniazid and ethambutol and proposed solutions
    Hemant Bhutani
    Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research, SAS Nagar, Punjab, India
    Drug Dev Ind Pharm 30:667-72. 2004
    ..The study suggests that barrier packaging free from defects and alternatively (or in combination) film coating of the tablets with water-resistant polymers are essential for this formulation...
  45. ncbi Stability of dolasetron in two oral liquid vehicles
    Cary E Johnson
    College of Pharmacy, University of Michigan, University of Michigan Hospitals and Health Centers, Ann Arbor, MI, USA
    Am J Health Syst Pharm 60:2242-4. 2003
    ..An extemporaneously compounded oral liquid preparation of dolasetron mesylate 10 mg/mL in a 1:1 mixture of Ora-Plus and strawberry syrup or Ora-Sweet was stable for at least 90 days when stored at 3-5 or 23-25 degrees C...
  46. ncbi Timed-release formulation to avoid drug-drug interaction between diltiazem and midazolam
    Toyohiro Sawada
    DDS Research, Novel Pharmaceutical Research Laboratories, Yamanouchi Pharmaceutical Company, Ltd, 180 Ozumi, Yaizu, Shizuoka 425 0072, Japan
    J Pharm Sci 92:790-7. 2003
    ....
  47. ncbi In vitro and in vivo evaluation of a sulfobutyl ether beta-cyclodextrin enabled etomidate formulation
    Michelle P McIntosh
    The Center for Drug Delivery Research, The University of Kansas, 2099 Constant Avenue, Lawrence, KS 66047, USA
    J Pharm Sci 93:2585-94. 2004
    ..The results suggest that the SBE-CD formulation is a viable clinical drug product with a reduced side-effect profile...
  48. ncbi Failure of stability prediction for minodronic acid injectable by accelerated stability testing
    Katsutoshi Nakamura
    Pharmaceutical Technology Laboratories and Novel Pharmaceutical Laboratories, Institute for Drug Development and Research, Yamanouchi Pharmaceutical Co, Ltd, 180 Ozumi Yaizu shi, 425 0072, Shizuoka ken, Japan
    Int J Pharm 241:65-71. 2002
    ..Since the particulate generation could not be observed at higher temperatures, it was suggested that the complex formation was exothermic and accelerated testing did not predict the stability in terms of particulate generation...
  49. ncbi Solution stability of factor Xa inhibitors as a function of pH
    Pei Yang
    Drug Development, Millennium Pharmaceuticals, Inc, Cambridge, Massachusetts 02139, USA
    Drug Dev Ind Pharm 30:967-73. 2004
    ..The mechanism of the reaction is not a specific-acid/base-catalyzed reaction. Based on the experience of this study, an ideal experimental design is proposed, which will be useful for future study on similar drug candidate...
  50. ncbi Challenges and opportunities in the encapsulation of liquid and semi-solid formulations into capsules for oral administration
    Ewart T Cole
    Capsugel Division of Pfizer, CH 4114 Hofstetten, Switzerland
    Adv Drug Deliv Rev 60:747-56. 2008
    ..Filling and sealing technologies for hard capsules, provides the formulator with the flexibility of developing formulations in-house from small scale, as required for Phase I studies, up to production...
  51. ncbi Nomenclature associated with chemical characterization of and compatibility evaluations for medical product delivery systems
    Dennis R Jenke
    Technology Resources, Baxter Healthcare Corporation, Round Lake, IL 60073, USA
    PDA J Pharm Sci Technol 57:97-108. 2003
    ..This manuscript puts forth a nomenclature which classifies those chemical entities which participate in the system/product interaction and delineates the various extraction strategies which may be used in compatibility assessments...
  52. ncbi Dissolution rate enhancement by adsorption of poorly soluble drugs on hydrophilic silica aerogels
    Irina Smirnova
    Fachgebiet Thermodynamik und Thermische Verfahrenstechnik, Institut fur Verfahrenstechnik, Technische Universitat Berlin, Berlin, Germany
    Pharm Dev Technol 9:443-52. 2004
    ..The dissolution rate of poorly water soluble drugs can be significantly enhanced by adsorption on highly porous hydrophilic silica aerogels...
  53. ncbi Stability of Ala 125 recombinant human interleukin-2 in solution
    Nuria Reyes
    Center for Genetic Engineering and Biotechnology, P O Box 6162, Havana, Cuba
    J Pharm Pharmacol 57:31-7. 2005
    ..Taken together, these preformulation results can be used to design an adequate liquid vehicle for rhIL-2A(125) to be manufactured for human use...
  54. ncbi Stability of flucytosine 50 mg/mL in extemporaneous oral liquid formulations
    Heather L Vandenbussche
    University of Michigan Hospitals and Health Centers UMHHC, Ann Arbor, USA
    Am J Health Syst Pharm 59:1853-5. 2002
  55. ncbi Compatibility of ondansetron hydrochloride and methylprednisolone sodium succinate in multilayer polyolefin containers
    Christelle Bougouin
    Pharmacy Service, Caremeau Hospital Medical Center, place du Professeur Debré, 3000 Nîmes, France
    Am J Health Syst Pharm 62:2001-5. 2005
    ..The compatibility of ondansetron hydrochloride and methylprednisolone sodium succinate in 5% dextrose injection and 0.9% sodium chloride injection was studied...
  56. ncbi Physicochemical characterization of ricobendazole: I. Solubility, lipophilicity, and ionization characteristics
    Zimei Wu
    School of Pharmacy, University of Otago, P O Box 913, Dunedin, New Zealand
    J Pharm Sci 94:983-93. 2005
    ....
  57. ncbi Inclusion complexation of diazepam with different cyclodextrins in formulations for parenteral use
    C Holvoet
    Department of Pharmaceutical Technology and Physical Pharmacy, Vrije Universiteit Brussel VUB Brussels, Belgium
    Pharmazie 60:598-603. 2005
    ..The stability of the preparations, with and without pH adjustment to pH 5, was investigated during 18 months and during this period no noticeable degradation was observed...
  58. ncbi Development of a simple method for predicting the levels of di(2-ethylhexyl) phthalate migrated from PVC medical devices into pharmaceutical solutions
    Yuji Haishima
    Division of Medical Devices, National Institute of Health Sciences, 1 18 1 Kamiyoga, Setagaya Ku, Tokyo 158 8501, Japan
    Int J Pharm 298:126-42. 2005
    ..significant proportional relationship exists between DEHP release potency and methyl yellow solubility of pharmaceutical solutions, and the risk of DEHP exposure to the patients administered pharmaceuticals through transfusion set could ..
  59. ncbi Rapid determination of lidocaine solutions with non-column chromatographic diode array UV spectroscopy and multivariate calibration
    Kent Wiberg
    AstraZeneca R and D Sodertalje, Analytical Development, Sodertalje, Sweden
    J Pharm Biomed Anal 30:1575-86. 2003
    A new method for the rapid determination of pharmaceutical solutions is proposed. A conventional HPLC system with a Diode Array Detector (DAD) was used with no chromatographic column connected. As eluent, purified water (Milli Q) was used...
  60. ncbi Insulin aspart (AspB28 human insulin) derivatives formed in pharmaceutical solutions
    Mette Uve Jars
    Protein Chemistry, BA, Novo Nordisk A S, Bagsvaerd, Denmark
    Pharm Res 19:621-8. 2002
    ..To isolate and identify the main insulin aspart (AspB28 human insulin) derivatives formed in pharmaceuticals (pH 7.4 at 5 degrees C), to estimate rates of formation, and to determine their biologic potencies...
  61. doi Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review
    Marc Port
    Guerbet, Research Division, Aulnay sous Bois, France
    Biometals 21:469-90. 2008
    ..stability, as demonstrated by numerous in vitro and in vivo studies, resulting in various formulations of pharmaceutical solutions of marketed contrast agents...
  62. ncbi Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice
    M V Papadopoulou
    The Radiation Medicine Institute, Evanston Northwestern Healthcare, IL 60201, USA
    Cancer Chemother Pharmacol 48:160-8. 2001
    ..Comparisons of schedule-dependent interactions between the hypoxic cytotoxins NLCQ-1/ tirapazamine (TPZ) and various chemotherapeutic drugs in BALB/c mice bearing EMT6 tumors...
  63. doi Effect of ethylenediamine on chemical degradation of insulin aspart in pharmaceutical solutions
    Christian Poulsen
    Pharmaceutics, Diabetes Department, Novo Nordisk A S, Novo Alle, room 6B1 58 1, 2880 Bagsvaerd, Denmark
    Pharm Res 25:2534-44. 2008
    ..To examine the effect of different amine compounds on the chemical degradation of insulin aspart at pharmaceutical formulation conditions...
  64. ncbi Modifying the bitterness of selected oral pharmaceuticals with cation and anion series of salts
    Russell S J Keast
    Monell Chemical Senses Center, Philadelphia, Pennsylvania 19104, USA
    Pharm Res 19:1019-26. 2002
    ..The purpose of this study was to examine the influence of a variety of cations and anions on the bitterness of selected oral pharmaceuticals and bitter taste stimuli: pseudoephedrine, ranitidine, acetaminophen, quinine, and urea...
  65. doi Significant improvement in sleep in people with intellectual disabilities living in residential settings by non-pharmaceutical interventions
    T Hylkema
    Coordinator sleep wake research Talant, 9244 ZN Beetsterzwaag, The Netherlands
    J Intellect Disabil Res 53:695-703. 2009
    ..Most available studies focus on pharmaceutical solutions. In this study we focus on improving sleep in people with intellectual disabilities living in residential ..
  66. ncbi Evaluation of model solvent systems for assessing the accumulation of container extractables in drug formulations
    D R Jenke
    Center for Physical and Chemical Sciences, Baxter Healthcare Inc, William Graham Science Center, Round Lake, IL 60073, USA
    Int J Pharm 224:51-60. 2001
    ..Of specific concern is the ability of device components to leach into the contacting solution. As pharmaceutical solutions containing surfactants, co-solvents and solubilizing agents become more common, method's for assessing ..
  67. doi Detection of IgG aggregation by a high throughput method based on extrinsic fluorescence
    Feng He
    Formulation and Analytical Resources, AW2 D3152, Amgen, Inc, 1201 Amgen Court West, Seattle, Washington, USA
    J Pharm Sci 99:2598-608. 2010
    ..This method may become a powerful high throughput tool to detect IgG aggregates in pharmaceutical solutions and to study other protein properties involving aggregation...
  68. ncbi Comparison between ropivacaine 1.5 mg ml(-1) plus fentanyl 2 mg ml(-1) and ropivacaine 1.5 mg ml(-1) plus clonidine 1 mg ml(-1) as analgesic solution after anterior cruciate ligament reconstruction: a randomized clinical trial
    Kalakonas Apostolos
    Department of Anaesthesiology 424 Teaching Military Hospital Thessaloniki, Periferiaki Odos N Eukarpia 56421, Greece
    Middle East J Anesthesiol 21:341-5. 2011
    ..Ropivacaine is commonly used as local anesthetic for postoperative analgesia through an epidural catheter. Data show that several adjuvants influence the analgesic effect of local anesthetic potency...
  69. ncbi Comparison of the therapeutic effectiveness of a dantrolene sodium solution and a novel nanocrystalline suspension of dantrolene sodium in malignant hyperthermia normal and susceptible pigs
    Jan K Schütte
    Department of Anaesthesiology and Intensive Care Medicine, Hospital Cologne Merheim, University of Witten Herdecke, Cologne, Germany
    Eur J Anaesthesiol 28:256-64. 2011
    ..The pig model is a well accepted method of studying the malignant hyperthermia crisis and is an ideal way to evaluate the variables of interest in this study...
  70. doi A randomized controlled trial of the effect of intrapartum intravenous fluid management on breastfed newborn weight loss
    Jo Watson
    Women and Babies Program, Sunnybrook Health Sciences Centre, Lawrence S Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada
    J Obstet Gynecol Neonatal Nurs 41:24-32. 2012
    ..To determine the effect of conservative versus usual intrapartum intravenous (IV) fluid management for low-risk women receiving epidural analgesia on weight loss in breastfed newborns...
  71. doi A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers
    Kenneth M Attie
    Department of Medical Research, Acceleron Pharma, Inc, 128 Sidney Street, Cambridge, Massachusetts 02139, USA
    Muscle Nerve 47:416-23. 2013
    ..ACE-031 is a soluble form of activin receptor type IIB (ActRIIB). ACE-031 promotes muscle growth by binding to myostatin and other negative regulators of muscle mass...
  72. doi Presence of phthalate esters in intravenous solution evaluated using gas chromatography-mass spectrometry method
    Ivona Vidić Strac
    Croatian National Institute of Public Health, Environmental Health Service, Zagreb, Croatia
    J Appl Toxicol 33:214-9. 2013
    ..Since phthalate esters are among the most extensively used industrial chemicals and are widely distributed in the environment, special precautions and further monitoring should be conducted to minimize any possible health risks...
  73. doi Stability of the ready-to-use solutions of eribulin for intravenous infusion
    S Poujol
    Oncopharmacology Laboratory, Val d Aurelle Cancer Centre, Parc Euromedecine, rue des Apothicaires, 34298 Montpellier, France
    Ann Pharm Fr 70:249-55. 2012
    ..Degradation was only found to occur under oxidation conditions...
  74. doi Efficacy of novel benznidazole solutions during the experimental infection with Trypanosoma cruzi
    Romina Manarin
    Instituto de Inmunologia, Santa Fe 3100, 2000 Rosario, Argentina
    Parasitol Int 62:79-81. 2013
    ..cruzi in a murine model of Chagas' disease. Present results constitute the first demonstration on the usefulness of benznidazole solutions in infected mice...
  75. ncbi Preparation of tripterine nanostructured lipid carriers and their absorption in rat intestine
    Lei Zhou
    Key Laboratory of New Drug Delivery System of Chinese Materia Medica, Jiangsu Provincial Academy of Chinese Medicine, Nanjing, PR China
    Pharmazie 67:304-10. 2012
    ..According to the result, the tripterine-loaded NLCs could greatly decrease the cytotoxicity of the drug. In conclusion, the NLC formulation remarkably improved the absorption of tripterine and showed a better biocompatibility...
  76. ncbi Study of formulation of pharmaceutical solution form of paracetamol in the pediatric clinical practice
    Bedri Abdullahu
    Department of Pharmacy, Faculty of Medicine, University of Prishtina, Clinical Centre, Prishtina, Kosova
    Med Arh 66:5-8. 2012
    ..AIM of the study was selection of 2 different formulations of paracetamol of 2.5% (125 mg/5 mL) in the Pediatric practice. Paracetamol is widely used in the form of the syrup, with usual percentage of acting ingredient of 125 mg/5 mL...
  77. doi Acceptability and compliance of atenolol tablet, compounded paste and compounded suspension prescribed to healthy cats*
    Kuan Hua Khor
    School of Veterinary Science, The University of Queensland, Gatton Campus, Queensland, Australia
    J Feline Med Surg 14:99-106. 2012
    ..Further work is now required to assess the amount and stability of the active ingredient and the robustness of the paste and suspension formulations prior to any bioavailability comparisons between the formulations...
  78. ncbi Improvement of pulmonary absorption of cyclopeptide FK224 in rats by co-formulating with beta-cyclodextrin
    Toshiomi Nakate
    Fujisawa Pharmaceutical Co, Ltd, Osaka, Japan
    Eur J Pharm Biopharm 55:147-54. 2003
    ..beta-CyD or derivatives with various degrees of aqueous solubility are potential drug carriers for controlling pulmonary absorption...
  79. ncbi The effect of taste masking agents on in situ gelling pectin formulations for oral sustained delivery of paracetamol and ambroxol
    Shozo Miyazaki
    Faculty of Pharmaceutical Sciences, Health Science University of Hokkaido, Ishikari Tohbetsu, Hokkaido 061 0293, Japan
    Int J Pharm 297:38-49. 2005
    ..Sustained release of ambroxol from in situ gelling formulations was achieved with pectin concentrations of 1.5 and 1% (w/v) and a sorbitol concentration of 10% (w/v)...
  80. ncbi Solution equilibria of deferoxamine amides
    Peter M Ihnat
    Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center 986025, Omaha, Nebraska 68198 6025, USA
    J Pharm Sci 91:1733-41. 2002
    ....
  81. ncbi Effective inhibition of mannitol crystallization in frozen solutions by sodium chloride
    Chitra Telang
    College of Pharmacy, 308 Harvard Street S E, University of Minnesota, Minnesota 55455, USA
    Pharm Res 20:660-7. 2003
    ..The purpose of this work was to study the possibility of preventing mannitol crystallization in frozen solutions by using pharmaceutically acceptable additives...
  82. doi Hydrosoluble medicated nail lacquers: in vitro drug permeation and corresponding antimycotic activity
    D Monti
    Department of Pharmaceutical Sciences, University of Pisa, Via Bonanno 33, I 56100 Pisa, Italy
    Br J Dermatol 162:311-7. 2010
    ..The present study aimed at evaluating the antimycotic activity of a new water-soluble nail lacquer containing CPX (CPX/sol), easily removable by washing with water and applicable to periungual skin...
  83. doi Albendazole treatment in cystic echinococcosis: pharmacokinetics and clinical efficacy of two different aqueous formulations
    Laura Ceballos
    Departamento de Fisiopatologia, Universidad Nacional del Centro de la Provincia de Buenos Aires, Campus Universitario, 7000, Tandil, Argentina
    Parasitol Res 103:355-62. 2008
    ..However, consistent with the observed PK results, both ABZ formulations were clinically effective in infected mice treated with a 12-h dosing interval (15 days therapy)...
  84. ncbi Biopharmaceutical considerations on antihistamine effects of topically administered emedastine
    Shoichi Harada
    Clinical Development Department, Nippon Organon K K, Dojima Avanza 14F, 1 6 20 Dojima, Kita ku, Osaka 530 0003, Japan
    J Pharm Sci 94:17-24. 2005
    ..The transdermal flux of the drug appears to be a good measure of its pharmacological effect...
  85. ncbi The dissolution of urinary catheter encrustation
    K A Getliffe
    European Institute of Health and Medical Sciences, University of Surrey, Guildford, UK
    BJU Int 85:60-4. 2000
    ..To identify the optimum volume of acidic bladder washout solution to dissolve catheter encrustations and to compare the effectiveness of different bladder washout delivery devices...
  86. doi A validated stability-indicating UPLC method for desloratadine and its impurities in pharmaceutical dosage forms
    Dantu Durga Rao
    Dr Reddy s Laboratories Ltd, IPDO, Bachupally, Hyderabad 500072, A P, India
    J Pharm Biomed Anal 51:736-42. 2010
    ..This method was also suitable for the assay determination of desloratadine in pharmaceutical dosage forms...
  87. ncbi Thermodynamic aspects of cluster crystallization in cryoprotective solutions
    A I Osetsky
    Institute for Problems of Cryobiology and Cryomedicine of the National Academy of Sciences of Ukraine, Kharkov, Ukraine
    Cryo Letters 32:216-24. 2011
    ..This should be taken into account when designing the cryopreservation protocols for biological systems...
  88. doi A smart interface for reliable intradermal injection and infusion of high and low viscosity solutions
    Michael Vosseler
    HSG IMIT, Wilhelm Schickard Str 10, 78052, Villingen Schwenningen, Germany
    Pharm Res 28:647-61. 2011
    ..Our solution enables injections or infusions that are less invasive compared to subcutaneous injections and are leakage-free at the location of penetration...
  89. doi Absorption pharmacokinetics of clonidine nasal drops in children
    Nicole Almenrader
    Department of Anaesthesia and Intensive Care, University Hospital, Policlinico Umberto I, Rome, Italy
    Paediatr Anaesth 19:257-61. 2009
    ..Effects and pharmacokinetics after oral, rectal, and intravenous administration are well known. The aim of this study was to investigate the absorption pharmacokinetics of clonidine nasal drops in children...
  90. ncbi Stability of buprenorphine, haloperidol and glycopyrrolate mixture in a 0.9% sodium chloride solution
    A Jäppinen
    Central Finland Hospital, Jyvaskyla, Finland
    Pharm World Sci 21:272-4. 1999
    ....
  91. ncbi [Morphology and function of platelets stored in modified platelet additive solution at low temperature]
    Xin Wang
    Department of Transfusion, Southwest Hospital, The Third Military Medical University, Chongqing, China
    Zhongguo Shi Yan Xue Ye Xue Za Zhi 17:797-801. 2009
    ..In short, PAS-IIIM serves as a good substitute of plasma for platelet storage, and protects the chilled platelets...
  92. doi Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs
    Masha S H Lam
    Hematology Oncology Infusion Clinic, Kaiser Permanente Health Plan, Antioch, California, USA
    Pharmacotherapy 31:164-92. 2011
    ....
  93. ncbi Characterization of glass solutions of poorly water-soluble drugs produced by melt extrusion with hydrophilic amorphous polymers
    A Forster
    School of Pharmacy, University of Otago, Dunedin, New Zealand
    J Pharm Pharmacol 53:303-15. 2001
    ..All extrudates remained amorphous when stored at 25 degrees C/< 10% RH. Differences in the physical stability of drug/polymer extrudates may be due to differences in H-bonding between the components...
  94. ncbi Oxidation of protein by vaporized sanitizing agents
    Wei Wang
    Analytics and Formulation, Biotechnology Division, Bayer HealthCare, Berkeley, CA 94701, USA
    PDA J Pharm Sci Technol 58:121-9. 2004
    ..These results strongly suggest that the sanitization process needs to be properly controlled and closely monitored during manufacturing of drug products that are sensitive to oxidation...
  95. ncbi Biological, pharmaceutical, and analytical considerations with respect to the transport media used in the absorption screening system, Caco-2
    Françoise M Ingels
    Biopharmaceutics and Drug Delivery, Lilly Development Centre, 11 rue Granbonpré, 1348 Mont Saint Guibert, Belgium
    J Pharm Sci 92:1545-58. 2003
    ..g., FASSIF) in combination with an analytically friendly, sink condition creating basolateral solvent (e.g., containing a micelle forming agent) can be suggested...
  96. ncbi Bioequivalence of a propylene glycol-based liquid dapsone preparation and dapsone tablets
    M Mirochnick
    Boston Medical Center Maternity 6, MA 02118, USA
    Am J Health Syst Pharm 57:1775-7. 2000
    ..Time to maximum serum concentration tended to be lower for the liquid, but not significantly. The liquid and tablet formulations of dapsone studied were found to be bioequivalent and may be used interchangeably...
  97. pmc A small peptide modeled after the NRAGE repeat domain inhibits XIAP-TAB1-TAK1 signaling for NF-κB activation and apoptosis in P19 cells
    Jennifer A Rochira
    University of Maine, Orono, Maine, United States of America
    PLoS ONE 6:e20659. 2011
    ..illustrate that the paradigm of the NRAGE repeat domain may hold promising therapeutic strategies in developing pharmaceutical solutions for combating harmful diseases involving excessive downstream BMP signaling, including apoptosis.
  98. doi Electroformation in a flow chamber with solution exchange as a means of preparation of flaccid giant vesicles
    Primoz Peterlin
    University of Ljubljana, Faculty of Medicine, Institute of Biophysics, Lipiceva 2, SI 1000 Ljubljana, Slovenia
    Colloids Surf B Biointerfaces 64:77-87. 2008
    ..Based on this result, an alternative mechanism is proposed for the observed exchange of vesicle interior. With modifications, the method of Estes and Mayer is then applied to preparation of flaccid GUVs...
  99. ncbi Alternative to liquid nitrogen for freezing skin lesions
    M Dean Havron
    Am Fam Physician 72:573; author reply 574. 2005
  100. ncbi Results of a randomised, multicentre study comparing a new water-based gel of clindamycin 1% versus clindamycin 1% topical solution in the treatment of acne vulgaris
    M Alirezai
    Montpellier, France
    Eur J Dermatol 15:274-8. 2005
    ..In conclusion, the new water-based gel once-a-day formulation of clindamycin 1% is an effective, safe, and convenient alternative to the twice-a-day topical solution formulation in the treatment of acne vulgaris...
  101. ncbi Preparation and rectal absorption of highly concentrated glycyrrhizin solution
    Kenjiro Koga
    Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokuriku University, Kanazawa, Japan
    Biol Pharm Bull 26:1299-305. 2003
    ..These results demonstrate that addition of a highly concentrated phosphate salts is effective not only for lowering the viscosity of a highly concentration of GZ solution, but also for improving the mucosal GZ absorption...

Research Grants23

  1. Clinical Investigation in Pediatric Thrombosis
    Neil Goldenberg; Fiscal Year: 2007
    ..Additionally, translational studies will seek to identify novel candidate protein risk factors and prognostic markers for venous thrombosis in children. ..
  2. Echinacea for Preventing Colds in Children
    James Taylor; Fiscal Year: 2007
    ..For the proposed project it is anticipated that 660 patients will be enrolled over a 42-month study period. ..
  3. MADMAX: Precise Measurement of Conformational Changes in Proteins
    Lee Makowski; Fiscal Year: 2009
    ..Application of this approach to molecular systems involved in pathogenesis will contribute significantly to the development of strategies for the diagnosis and treatment of a broad range of human diseases. ..
  4. CHILDREN'S CENTER FOR CLINICAL PHARMACOLOGY STUDIES
    Gregory Kearns; Fiscal Year: 2007
    ..abstract_text> ..
  5. Antiretroviral Pharmacology/Lactating Mother/Infants
    Mark Mirochnick; Fiscal Year: 2006
    ..This information is needed for the safe and effective use of antiretrovirals in nursing women, and will pioneer a novel approach to the study of breast milk drug transfer. ..
  6. Reducing Mortality from Acute Hemorrhage in Trauma
    John Hess; Fiscal Year: 2006
    ..Reducing death from acute hemorrhage in trauma care will be a major step forward in reducing overall trauma mortality. ..
  7. A RANDOMIZED CONTROLLED TRIAL OF ECHINACEA IN CHILDREN
    James Taylor; Fiscal Year: 2001
    ..abstract_text> ..
  8. PSYCHOPHYSICAL INVESTIGATION OF UMAMI TASTE
    Russell Keast; Fiscal Year: 2004
    ..abstract_text> ..
  9. Elucidation of the Lipoxygenase-Mediated Pathway of Lun*
    PAUL MYRDAL; Fiscal Year: 2005
    ..abstract_text> ..
  10. Digoxin Chiral Isolates as Improved Pharmaceuticals
    John Somberg; Fiscal Year: 2005
    ..The advantage would be a treatment for AF that did not cause cardiac augmentation and vasoconstriction or a treatment for CHF that does not cause heart rate slowing or conduction disturbances. ..
  11. The Feasibility of Assessing the Prevalence of Rickets
    James Taylor; Fiscal Year: 2006
    ..In addition to assessing possible methodologies for the larger project, the preliminary study is designed to yield standalone results with important implications. ..
  12. Bronx-Lebanon Hospital Center Pediatric ACTU
    Murli Purswani; Fiscal Year: 2006
    ..abstract_text> ..
  13. Host-Response Relationships in Patients with Candidemia
    Melissa Johnson; Fiscal Year: 2006
    ....
  14. Bronx-Lebanon Hospital Clinical Trials Unit
    Murli Purswani; Fiscal Year: 2007
    ..administrative component: ..
  15. MADMAX: Precise Measurement of Conformational Changes in Proteins
    Lee Makowski; Fiscal Year: 2010
    ..Application of this approach to molecular systems involved in pathogenesis will contribute significantly to the development of strategies for the diagnosis and treatment of a broad range of human diseases. ..